Novel GM1 ganglioside-like peptide mimics prevent the association of cholera toxin to human intestinal epithelial cells in vitro

Glycobiology

Volumn 26, Issue 1, 2015, Pages 63-73

  Yu, Robert K ^a,b   Usuki, Seigo ^a,b,d   Itokazu, Yutaka ^a,b   Wu, Han Chung ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

bacterial infection; cAMP; cholera toxin; epithelial cell; GM1 ganglioside

Indexed keywords

CHOLERA TOXIN; GANGLIOSIDE GM1; PEPTIDE FRAGMENT; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BINDING AFFINITY; BIOPANNING; CHOLERA; COMPETITIVE INHIBITION; CONCENTRATION CAMP; DNA SEQUENCE; IC50; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; VIBRIO CHOLERAE; CACO-2 CELL LINE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR MIMICRY; SYNTHESIS;

CACO-2 CELLS; CHOLERA TOXIN; G(M1) GANGLIOSIDE; HUMANS; MOLECULAR MIMICRY; PEPTIDE FRAGMENTS; PROTEIN BINDING;

EID: 84957448741     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwv080     Document Type: Article

References (33)

1. Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, Clemens J. 2012. The global burden of cholera. Bull World Health Organ. 90:209-218A.
2. Ariga T, Kobayashi K, Kuroda Y, Yu RK, Suzuki M, Kitagawa H, Inagaki F, Miyatake T. 1987. Characterization of tumor-associated fucogangliosides from PC 12 pheochromocytoma cells. J Biol Chem. 262:14146-14153.
3. Ariga T, Kohriyama T, Freddo L, Latov N, Saito M, Kon K, Ando S, Suzuki M, Hemling ME, Rinehart KL Jr, et al. 1987. Characterization of sulfated glucuronic acid containing glycolipids reacting with IgM M-proteins in patients with neuropathy. J Biol Chem. 262:848-853.
4. Cheng Y, Prusoff WH. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 22:3099-3108.
5. Dawson RM. 2005. Characterization of the binding of cholera toxin to ganglioside GM1 immobilized onto microtitre plates. J Appl Toxicol. 25:30-38.
6. Fogh J, Trempe G. 1975. New human tumor cell lines. In: Fogh J, editor. Human Tumor Cells In Vitro. New York: Plenum Publishering Group. p. 115-141.
7. Hill AV. 1910. The possible effects of the aggregation of the molecules of hemoglobin on its dissociation curves. J Physiol. 40: iv-vii.
8. Holmgren J, Lonnroth I, Svennerholm L. 1973. Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids. Infect Immun. 8: 208-214.
9. Horstman AL, Bauman SJ, Kuehn MJ. 2004. Lipopolysaccharide 3-deoxy-D-manno-octulosonic acid (Kdo) core determines bacterial association of secreted toxins. J Biol Chem. 279:8070-8075.
10. King AA, Ionides EL, Pascual M, Bouma MJ. 2008. Inapparent infections and cholera dynamics. Nature. 454:877-880.
11. Kuziemko GM, Stroh M, Stevens RC. 1996. Cholera toxin binding affinity and specificity for gangliosides determined by surface plasmon resonance. Biochemistry. 35:6375-6384.
12. Ledeen RW, Yu RK. 1982. Gangliosides: structure, isolation, and analysis. Methods Enzymol. 83:139-191.
13. Lencer WI, Tsai B. 2003. The intracellular voyage of cholera toxin: going retro. Trends Biochem Sci. 28:639-645.
14. MinkeWE, Hong F, Verlinde CL,HolWG, Fan E. 1999. Using a galactose library for exploration of a novel hydrophobic pocket in the receptor binding site of the Escherichia coli heat-labile enterotoxin. J Biol Chem. 274:33469-33473.
15. Mitchell DD, Pickens JC, Korotkov K, Fan E, Hol WG. 2004. 3,5-Substituted phenyl galactosides as leads in designing effective cholera toxin antagonists; synthesis and crystallographic studies. Bioorg Med Chem. 12:907-920.
16. Orlandi PA, Curran PK, Fishman PH. 1993. Brefeldin A blocks the response of cultured cells to cholera toxin. Implications for intracellular trafficking in toxin action. J Biol Chem. 268:12010-12016.
17. Sack DA, Sack RB, Nair GB, Siddique AK. 2004. Cholera. The Lancet. 363:223-233.
18. Simon-Haldi M, Mantei N, Franke J, Voshol H, Schachner M. 2002. Identification of a peptide mimic of the L2/HNK-1 carbohydrate epitope.JNeurochem. 83:1380-1388.
19. Sixma TK, Pronk SE, Kalk KH, van Zanten BA, Berghuis AM, Hol WG. 1992. Lactose binding to heat-labile enterotoxin revealed by X-ray crystallography. Nature. 355:561-564.
20. Spangler BD. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev. 56:622-647.
21. Sundaram U, Knickelbein RG, Dobbins JW. 1991. Mechanism of intestinal secretion: effect of cyclic AMP on rabbit ileal crypt and villus cells. Proc Natl Acad Sci USA. 88:6249-6253.
22. Taki T, Ishikawa D, Ogino K, Tanaka M, Oku N, Asai T, Popa I, Portoukalian J. 2008. A new approach for drug discovery from glycobiology and phage-displayed peptide library technology. Biochim Biophys Acta. 1780:497-503.
23. Thompson JP, Schengrund CL. 1998. Inhibition of the adherence of cholera toxin and the heat-labile enterotoxin of Escherichia coli to cell-surface GM1 by oligosaccharide-derivatized dendrimers. Biochem Pharmacol. 56:591-597.
24. Tsai B, Ye Y, Rapoport TA. 2002. Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat Rev Mol Cell Biol. 3:246-255.
25. Usuki S, Pajaniappan M, Thompson SA, Yu RK. 2007. Chemical validation of molecular mimicry: interaction of cholera toxin with Campylobacter lipooligosaccharides. Glycoconj J. 24:167-180.
26. Usuki S, Taguchi K, Cawthraw SA, Shibata K, Ariga T, Newell DG, Yu RK. 2006. Human and chicken antibodies to gangliosides following infection by Campylobacter jejuni. Exp Neurol. 200:50-55.
27. Usuki S, Taguchi K, Gu YH, Thompson SA, Yu RK. 2010. Development of a novel therapy for Lipo-oligosaccharide-induced experimental neuritis: use of peptide glycomimics. J Neurochem. 113:351-362.
28. Wagner JG. 1968. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol. 20:173-201.
29. Welsh MJ, Smith PL, Fromm M, Frizzell RA. 1982. Crypts are the site of intestinal fluid and electrolyte secretion. Science. 218:1219-1221.
30. Wernick NL, Chinnapen DJ, Cho JA, Lencer WI. 2010. Cholera toxin: an intracellular journey into the cytosol by way of the endoplasmic reticulum. Toxins (Basel). 2:310-325.
31. Wu CH, Kuo YH, Hong RL, Wu HC. 2015. Alpha-enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer. Sci Transl Med. 7:290ra291.
32. Yanagisawa M, Ariga T, Yu RK. 2006. Cholera toxin B subunit binding does not correlate with GM1 expression: a study using mouse embryonic neural precursor cells. Glycobiology. 16:19G-22G.
33. Yu RK, Usuki S, Ariga T. 2012. Anti-glycolipid Antibodies in Guillain-Barré Syndrome and Related Neuropathies: Therapeutic strategies for disease treatment. Anticarbohydrate antibodies. Vienna: Springer. p. 327-359.